DALI PHARMACEUTICAL(SH:603963)2020-10-29 16:00Financial Performance - Operating revenue decreased by 29.36% to CNY 162,038,974.79 for the first nine months of the year[5] - Net profit attributable to shareholders decreased by 81.58% to CNY 1,275,879.51 for the first nine months[5] - Basic and diluted earnings per share decreased by 67.16% to CNY 0.0220[6] - The company's operating revenue for the first nine months of 2020 was ¥162,038,974.79, a decrease of 29.36% compared to ¥229,385,494.19 in the same period of 2019, primarily due to reduced sales impacted by the COVID-19 pandemic[10] - Net profit for the first nine months of 2020 was ¥4,835,176.83, down 67.15% from ¥14,719,734.19 in the previous year, attributed to the decline in sales[10] Cash Flow - Cash flow from operating activities improved, with a net cash flow of CNY -7,693,133.46 compared to CNY -10,038,209.17 in the same period last year[5] - The cash flow from financing activities for the first nine months of 2020 was ¥19,749,416.67, compared to a negative cash flow of ¥10,010,000.00 in the same period of 2019, driven by new borrowings for the technology complex project[11] Assets and Liabilities - Total assets increased by 3.85% to CNY 582,937,725.37 compared to the end of the previous year[5] - The company reported a significant increase in accounts payable, rising 117.54% to ¥29,901,791.19, mainly due to increased construction costs for the technology complex project[10] - Deferred income increased by 2414.73% to ¥867,374.79, primarily due to an increase in fair value gains during the reporting period[10] - The company’s long-term borrowings reached ¥20,133,374.78, attributed to new loans for the technology complex project[10] Shareholder Information - The total number of shareholders reached 12,875[7] - The top shareholder, Yang Junxiang, holds 25.50% of the shares, totaling 56,023,500 shares[7] Other Income and Expenses - The company reported a government subsidy of CNY 373,909.97 for the year-to-date[8] - Non-operating income for the first nine months totaled CNY 3,559,297.32[8] - The company reported a decrease in sales expenses by 34.08% to ¥94,649,365.87, reflecting reduced market and academic promotion activities[10] - The company experienced a 40.93% reduction in taxes and surcharges, totaling ¥2,614,420.46, due to decreased turnover taxes[10] Capital Changes - The capital reserve decreased by 30.09% to ¥117,799,200.00, mainly due to the transfer of capital reserves to increase capital[10] Commitments and Warnings - The company did not report any significant changes in commitments or warnings regarding potential losses for the upcoming reporting period[11] Prepayments - Prepayments increased significantly by 143.47% to CNY 3,095,930.93 due to payments for equipment purchases[9]